Prognostic Value of Androgen Receptor in Triple Negative Breast Cancer of Iranian Patients in Yazd Region

Main Article Content

Fatemeh Alsadat Nobakht
Mansour Moghimi


AR, TNBC, Immunohistochemistry, Yazd Patients


Background: Triple negative breast cancer (TNBC) is a heterogeneous disease group with a higher recurrence risk and poorer prognosis. In this study, we aimed to investigate the frequency and prognostic value of androgen receptor (AR) expression in tissues of TNBC patients.
Methods: In this study a total of 60 TNBC patients treated between 2011 - 2016 in Shahid Sadoughi and Mortaz Hospital were included and their medical records were analyze. The available paraffin blocks were assessed immunohistochemically to determine AR expression. Tumors with ?10% nuclear staining were considered AR-positive, while the ones with <10% staining were considered AR-negative. The association between AR expression, and clinical-pathologic characteristics and prognosis in TNBC was analyzed.
Results: The result showed that AR expression in TBNC correlated with high risk of recurrence but no significant correlation with the age, grade, tumor size, lymph node status, type of diagnosis, tumor location, and Ki-67 level was observed. Positive immunoreactivity for AR was observed in 19 out of 60 (11%) specimens. No correlation was observed between the AR expression and the age, grade, tumor size, lymph node status, type of diagnosis, tumor location, and Ki-67 level. The AR-positive patients exhibited high risk of recurrence (P=0.016) and death (P=0.015) in comparison with the AR-negative patients.
Concusions: AR may not be a suitable biomarker and treatment target for the Iranian Yazd patients with TNBC.


1. Reis?Filho J, Tutt A. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108-18.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
3. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. EMHJ-Eastern Mediterranean Health Journal, 15 (6), 1426-1431, 2009. 2009.
4. Aghili M, Lashkari M, Farrokhpey AH, Izadi S. Triple-negative breast cancer survival in Iranian patients. Acta Medica Iranica. 2013:560-6.
5. Perez EA. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist. 2011;16 Suppl 1:20-2.
6. Bernard-Marty C, Lebrun F, Awada A, Piccart MJ. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs. 2006;66(12):1577-91.
7. Mohammadizadeh F, Sajadieh S, Sajjadieh H, Kasaei Z. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. Adv Biomed Res. 2014;3:132.
8. Jam S, Abdollahi A, Zand S, Khazaeipour Z, Omranipour R, et al. Androgen Receptor Expression in Triple-Negative Breast Cancer. Archives of Breast Cancer. 2019:92-5.
9. Naimi A, Sultan M, Amjadi E, Goli P, Kefayat A. Androgen Receptor Expression and Its Correlation with Clinicopathological Parameters in Iranian Patients with Triple Negative Breast Cancer. Iranian Journal of Pathology. 2020:239-44.
10. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, et al. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017;3(9):1266-73.
11. Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, et al. The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clinical Cancer Research. 2018;24(10):2328-41.
12. Aleskandarany MA, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, et al. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast cancer research and treatment. 2016;159(2):215-27.